



UNIVERSITY OF MICHIGAN
CLINICAL DRUG PIPELINE

M INNOVATION PARTNERSHIPS **M** UNIVERSITY OF MICHIGAN
UNIVERSITY OF MICHIGAN

Product	Company	Indication	Pre-Clinical	Phase I	Phase II	Phase III*	Marketed
Amevive	Astellas	chronic plaque psoriasis					2003
BEXXAR	GSK	non-hodgkin's lymphoma					2003
FluMist Quadrivalent	AstraZeneca	influenza vaccine					2003
Orencia	Bristol Meyers Squibb	rheumatoid arthritis					2005
Cerdelga eliglustat	Sanofi	Gaucher's disease					2014
Auryxia	Akebia	chronic kidney disease					2014
Kymriah	Novartis	leukemia, lymphoma					2017
Livtency	Takeda Pharmaceuticals	CMV					2021
TAK-755	Takeda Pharmaceuticals	CTTP					2023
Xevinapant	Merck KGaA	cancer					
Reparixin	Dompe Farmaceutici	breast cancer					
Lisaftoclax	Ascentage Pharma	cancer					
Ziftomenib	Kura Oncology	leukemia					
CLR 131	Collectar Biosciences	leukemia, lymphoma					
Alrizomadlin	Ascentage Pharma	cancer					
Pelcitoclax	Ascentage Pharma	cancer & fibrosis					
APG-1387	Ascentage Pharma	hepatitis B					
ONL 1204	ONL Therapeutics	retinal, glaucoma					
TNX-1300	Tonix Pharmaceuticals	cocaine intoxication					
ESK981	Esanik Therapeutics	prostate cancer					



Product	Company	Indication	Pre-Clinical	Phase I	Phase II	Phase III*	Marketed
LP-182	Lympharma	cancer					
CS-585	Cereno Scientific	cardiovascular					
TBD	STEALTH	retinal degeneration					
ATX101	Abcon Therapeutics, Inc.	T cell lymphoma					
TBD	Esperovax, Inc.	VLP vaccines					
TBD	KOR Life Sciences, LLC	cancer					
TBD	Molecure	fibrosis					
TBD	TenSixteen Bio	age-related diseases					
TBD	STEALTH	cataracts					
TBD	Kinesid Therapeutics	anemia					
Anti-CitH3 Antibody	STEALTH	immune, cancer, inf. disease					
TBD	STEALTH	cancer					

**or other "registration directed" trial. "Registration directed" refers to a clinical trial which determines whether a pharmaceutical is safe for human use, regardless of official denomination as a Phase III trial.*